A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1, dose-escalation study to determine the recommended doses of
STA-9090 (ganetespib) and docetaxel for the treatment of subjects with solid tumor
malignancies. The safety and tolerability of the treatment will also be evaluated.